Patents by Inventor Stefan FADERL

Stefan FADERL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS
    Publication number: 20240252522
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.
    Type: Application
    Filed: September 25, 2019
    Publication date: August 1, 2024
    Applicant: Celator Pharmaceuticals, Inc.
    Inventors: Ronald CHEUNG, Stefan FADERL, Qi WANG
  • TREATMENT OF HEMATOLOGICAL DISORDERS
    Publication number: 20240252526
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.
    Type: Application
    Filed: April 10, 2024
    Publication date: August 1, 2024
    Inventor: Stefan FADERL
  • Treatment of hematological disorders
    Patent number: 11980636
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: May 14, 2024
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Stefan Faderl
  • TREATMENT OF HEMATOLOGICAL DISORDERS
    Publication number: 20220152074
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 19, 2022
    Inventor: Stefan FADERL
  • LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS
    Publication number: 20210393665
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.
    Type: Application
    Filed: June 3, 2021
    Publication date: December 23, 2021
    Applicant: Celator Pharmaceuticals, Inc.
    Inventors: Ronald CHEUNG, Stefan FADERL, Qi WANG